nct_id: NCT05552222
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-09-23'
study_start_date: '2022-10-25'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Teclistamab'
  - drug_name: 'Drug: Dexamethasone'
  - drug_name: 'Drug: Daratumumab'
  - drug_name: 'Drug: Talquetamab'
  - drug_name: 'Drug: Lenalidomide'
long_title: A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab
  SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC
  and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone
  (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible
  or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
last_updated: '2025-11-07'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Janssen Research & Development, LLC
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 1590
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Have a diagnosis of multiple myeloma according to the International Myeloma Working
  Group (IMWG) diagnostic criteria'
- '* Be newly diagnosed and not considered a candidate for high-dose chemotherapy
  with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age
  OR; ineligible due to the presence of comorbid condition(s) likely to have a negative
  impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose
  chemotherapy with ASCT as initial treatment'
- '* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of
  0 to 2'
- '* A participant must agree not to be pregnant, breastfeeding, or planning to become
  pregnant while enrolled in this study or within 6 months after the last dose of
  study treatment'
- '* A participant must agree not to plan to father a child while enrolled in this
  study or within 100 days after the last dose of study treatment'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Received any prior therapy for multiple myeloma or smoldering myeloma
  other than a short course of corticosteroids (not to exceed total of 160 milligrams
  \[mg\] dexamethasone or equivalent). In addition, received a cumulative dose of
  systemic corticosteroids equivalent to greater than or equals to (\>=) 20 mg of
  dexamethasone within 14 days before randomization
- Exclude - * Had plasmapheresis within 28 days of randomization
- Exclude - * Had a stroke, transient ischemic attack, or seizure within 6 months
  prior to randomization
- Exclude - * Known allergies, hypersensitivity, or intolerance to teclistamab or
  talquetamab excipients
- Exclude - * Known contraindications to the use of daratumumab or lenalidomide per
  local prescribing information
- Exclude - * Myeloma Frailty Index of \>=2 with the exception of participants who
  have a score of 2 based on age alone
short_title: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide
  (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR)
  in Participants With Newly Diagnosed Multiple Myeloma
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Janssen Research & Development, LLC
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to compare the efficacy of teclistamab in combination
  with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab
  and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Teclistamab, Daratumumab SC, and Lenalidomide (Tec-DR)
      arm_internal_id: 0
      arm_description: Participants will receive teclistamab as subcutaneous (SC)
        injection in combination with daratumumab and lenalidomide.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Teclistamab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Daratumumab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Lenalidomide'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Talquetamab, Daratumumab SC, and Lenalidomide (Tal-DR)
      arm_internal_id: 1
      arm_description: Participants will receive talquetamab as SC injection in combination
        with daratumumab and lenalidomide.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Daratumumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenalidomide'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Talquetamab'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)
      arm_internal_id: 2
      arm_description: Participants will receive daratumumab as SC injection with
        lenalidomide and dexamethasone.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Daratumumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenalidomide'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Dexamethasone'
        level_internal_id: 2
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Untreated
        oncotree_primary_diagnosis: Lymphoid Neoplasm
